Rage Biotech

Executive Summary

Rage Biotech is an Australian preclinical biotech developing RNA-based therapeutics that modulate the Receptor for Advanced Glycation End-products (RAGE) using splice-switching oligonucleotides. The company's platform shifts RAGE from a pro-inflammatory to an anti-inflammatory isoform, addressing significant unmet needs in chronic inflammatory diseases. Founded in 2020 and based in Melbourne, Rage Biotech combines cutting-edge RNA-targeting chemistry with a translational medicine approach. Its innovative strategy has the potential to yield first-in-class therapies for conditions driven by RAGE-mediated inflammation. Currently in preclinical development, Rage Biotech is advancing its lead candidates toward IND-enabling studies. Key near-term milestones include generating in vivo efficacy data and completing regulatory toxicology assessments. The company is also pursuing Series A financing to support these efforts. Success in these milestones would de-risk the platform and enable progression toward clinical trials, positioning Rage Biotech as a promising player in the immunology and inflammation space. However, as a preclinical-stage company with no disclosed financials or pipelines, execution risk remains high.

Upcoming Catalysts (preview)

• Q3 2026Preclinical in vivo efficacy data readout40% success
• Q4 2026IND-enabling studies completion30% success
• Q2 2026Series A funding round50% success